ClinicalTrials.gg
CompletedNCT05231278CLEARUpdated May 13, 2026

Confocal Laser Endomicroscopy Nodule Localization by Robotic Bronchoscopy

An interventional study of nCLE aided RANB biospy in Lung Neoplasms, sponsored by Johnson & Johnson Enterprise Innovation Inc.. Completed at 4 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Johnson & Johnson Enterprise Innovation Inc. (part of Johnson & Johnson) · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was Oct 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Lung Neoplasms by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Lung Neoplasms · Johnson & Johnson.

Enrollment
4th of 10
53 · median 13
Started
2022
with 2 others
No phase
8 of 12
none open now
Registered
10th of 12
by date

Among the 12 studies in Lung Neoplasms by Johnson & Johnson, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2022, is one of 8 with no phase, and was the 10th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

None of the 12 studies in Lung Neoplasms by Johnson & Johnson is open now. The open studies under Lung Neoplasms, anywhere →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Lung Neoplasms by Johnson & Johnson as a file.
02

Study summary

This study is designed to evaluate the safety and feasibility of real-time needle-based confocal laser endomicroscopy (nCLE) in improving diagnostic accuracy of robotic-assisted bronchoscopy (RANB) biopsy performed with the Monarch® Endoscopy Platform in patients with peripheral pulmonary nodules (PPN).

Read the detailed description

Robotic-assisted navigational bronchoscopy (RANB) improves accuracy of lesion localization and diagnostic yield of the peripheral pulmonary nodule (PPN) biopsy compared to conventional flexible bronchoscopy. Needle based confocal laser endomicroscopy (nCLE) allows real-time microstructural imaging of lung nodule tissues at the needle tip. The study is designed to evaluate the safety and feasibility of utilizing nCLE during RANB biopsy procedure to optimize needle position and diagnostic accuracy, as well as reduce or replace the need for additional imaging tools such as radial endobronchial ultrasound (r-EBUS), cone beam computed tomography (CBCT), and/or fluoroscopy during RANB biopsy.

03

Conditions studied

  • Lung Neoplasms

Browse trials for

Keywords

  • Peripheral pulmonary nodule
  • Needle-based confocal laser endomicroscopy
  • Robotic-assisted bronchoscopy
  • Monarch
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 22 years at signing of form (ICF).
  • Undergoing standard-of-care RANB for a solid lung nodule, which is considered to be at intermediate- to high-risk for as determined by the investigator per the institution's standard of care.
  • ICF signed before any study procedures are initiated.

Exclusion criteria

Exclusion Criteria:

  • Medical to bronchoscopy under general anesthesia, or lack of physical fitness to undergo bronchoscopy under general anesthesia or to follow the study processes, as assessed by the investigator.
  • Presence of uncorrectable bleeding disorders, or anticoagulation/anti- aggregation therapy that cannot be withheld for an appropriate interval prior to the procedure, as defined per the institution's standard of care.
  • Medical devices interfering with electro-magnetic navigation, including but not limited to pacemakers.
  • Subjects who have a target lesion that shows endobronchial involvement on chest CT.
  • Participation in any other clinical trial within 30 days of enrollment, that would interfere with this study.
  • Known to fluorescein sodium or any other ingredients in the fluorescein product.
  • Planned surgical resection at the time of bronchoscopy
  • Female subjects who are pregnant or nursing at the time of the procedure.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    nCLE aided RANB biopsy

    Single arm study

    Device: nCLE aided RANB biospy

Interventions

  • DevicenCLE aided RANB biospy

    nCLE aided RANB biopsy procedure using the Monarch® robotic-assisted navigational bronchoscopy platform and Cellvizio® I.V.E. system with AQ-Flex™ 19 Confocal Miniprobe™ used in combination with Fluorescein.

06

What researchers measure

Primary outcomes

  1. Feasibility as Assessed by Proportion of Participants with Accurate 'Tool-in-lesion' Position During Needle-based Confocal Laser Scanning Endomicroscopy (nCLE)-Aided Robotic-Assisted Navigational Bronchoscopy (RANB)

    Cone-beam computed tomography (CBCT) is used to determine the accuracy of the 'tool-in-lesion' position as obtained during nCLE-aided bronchoscopy.

    Time frame: Intra-procedure

Secondary outcomes

  1. Sensitivity of the real-time nCLE imaging assessment for malignancy

    The real-time nCLE imaging assessment of the index PPN for malignancy will be compared to the histopathology biopsy results of the index PPN.

    Time frame: Intra-procedure

  2. Diagnostic yield

    Diagnostic yield for all nCLE aided RANB biopsy performed for the index PPN will be evaluated based on histopathological assessment of acquired tissue samples.

    Time frame: up to 12 months post procedure

  3. Sensitivity of the post-procedure nCLE image assessment for malignancy

    The post-procedure nCLE image assessment of the index PPN for malignancy will be compared to the histopathology biopsy results of the index PPN.

    Time frame: Intra-procedure

  4. Intra- and inter-observer agreement of the post-procedure nCLE imaging for malignancy

    The post-procedure nCLE image assessment of the index PPN will be obtained by multiple independent, blinded raters; the intra- and interobserver agreement will be determined.

    Time frame: Intra-procedure

  5. Safety of nCLE aided RANB biopsy procedure

    The safety of nCLE aided RANB biopsy procedure will be reported as the number and frequency of adverse events (AEs) and procedure-related AEs.

    Time frame: up to 30 days post procedure

07

Study locations

4 sites
  • John Muir Health
    Concord, California 94520, United States
  • Clinical Research Associates of Central PA
    Altoona, Pennsylvania 16602, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Fox Chase Cancer Center of the American Oncologic Hospital, Inc.
    Philadelphia, Pennsylvania 19129, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Oct 2023, 20 months.

Of 51 industry-sponsored interventional studies with no phase under Lung Neoplasms, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 20 months is above that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2022
First posted
Feb 9, 2022
StartActual
Jan 20, 2022
Primary completionActual
Oct 12, 2023
CompletionActual
Sep 6, 2024
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05231278
Responsible party
Sponsor
First posted
Feb 9, 2022
Start date
Jan 20, 2022
Primary completion
Oct 12, 2023
Completion
Sep 6, 2024
Last update
May 13, 2026

Study contacts

Balaji Laxmanan, MD
study director · Johnson & Johnson Enterprise Innovation Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion